The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer
-
Published:2024-01-25
Issue:
Volume:
Page:
-
ISSN:0167-6806
-
Container-title:Breast Cancer Research and Treatment
-
language:en
-
Short-container-title:Breast Cancer Res Treat
Author:
Çetin KenanORCID, Kökten ŞerminORCID, Sarıkamış BaharORCID, Yıldırım Sedat, Gökçe Oruç NumanORCID, Barışık Nagehan ÖzdemirORCID, Kılıç ÜlkanORCID
Abstract
Abstract
Purpose
Achieving a pathological complete response (pCR) after neoadjuvant therapy in HER2-positive breast cancer patients is the most significant prognostic indicator, suggesting a low risk of recurrence and a survival advantage. This study aims to investigate clinicopathological parameters that can predict the response to neoadjuvant treatment in HER2 + breast cancers and to explore the roles of tumour-infiltrating lymphocytes (TILs), CD8 + T lymphocytes and PD-L1 expression.
Methods
This single-centre retrospective study was conducted with 85 HER2-positive breast cancer patients who underwent surgery after receiving neoadjuvant therapy between January 2017 and January 2020. Paraffin blocks from these patients were selected for immunohistochemical studies.
Results
A complete pathological response to neoadjuvant treatment was determined in 39 (45.9%) patients. High Ki-67 index (> 30%), moderate to high TIL infiltration, PD-L1 positivity and high CD8 cell count (≥ 25) were significantly associated with pCR in univariate analyses (p: 0.023, 0.025, 0.017 and 0.003, respectively). Multivariate regression analysis identified high Ki-67 index (> 30%) and CD8 cell infiltration as independent predictors for pCR in HER2-positive breast cancer.
Conclusions
High Ki-67 index, and high CD8 cell count are strong predictors for pCR in HER2-positive breast cancer. Tumours with high Ki-67 index, high TILs and CD8 infiltration may represent a subgroup where standard therapies are adequate. Conversely, those with low TILs and CD8 infiltration may identify a subgroup where use of novel strategies, including those that increase CD8 infiltration could be applied.
Funder
Canakkale Onsekiz Mart University
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference43 articles.
1. GLOBOCAN (2020) New global cancer data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data (Accessed on November 24, 2022) 2. Slamon D, Pegram M (2001) Rationale for trastuzumab (herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3):13–19. https://doi.org/10.1016/s0093-7754(01)90188-5 3. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J (2013) Pertuzumab plus Trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol: Off J Eur Soc Med Oncol 24(9):2278–2284. https://doi.org/10.1093/annonc/mdt182 4. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32. https://doi.org/10.1016/S1470-2045(11)70336-9 5. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after Neoadjuvant Chemotherapy Associated with residual Cancer burden and breast Cancer subtype. J Clin Oncol: Off J Am Soc Clin Oncol 35(10):1049–1060. https://doi.org/10.1200/JCO.2015.63.1010
|
|